Showing results (61-70 of 118) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2017
American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology WorkforceKaren M Winkfield, Christopher R Flowers, Jyoti D Patel, et al.Lung Cancer (Amsterdam, Netherlands)|April 14, 2023
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutationsPetros Christopoulos, Thibaud Prawitz, Jin-Liern Hong, et al.JCO Precision Oncology|January 27, 2022
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung CancersAlexander Drilon, Daniel S W Tan, Ulrik N Lassen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 23, 2015
Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerDavid R Spigel, Jyoti D Patel, Craig H Reynolds, et al.JTO Clinical and Research Reports|September 30, 2021
Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLCThomas A Hensing, Xiaofei Wang, Thomas E Stinchcombe, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLCJyoti Malhotra, Petros Nikolinakos, Ticiana Leal, et al.Clinical and Translational Science|December 19, 2020
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung CancerJonathan W Goldman, Minal Barve, Jyoti D Patel, et al.JCO Precision Oncology|February 9, 2022
Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case SeriesMiriam T Jacobs, Nisha A Mohindra, Lindsey Shantzer, et al.Clinical Lung Cancer|December 18, 2014
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung CancerCraig H Reynolds, Jyoti D Patel, Edward B Garon, et al.Cancer Discovery|October 4, 2016
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung CancerMagda Bahcall, Taebo Sim, Cloud P Paweletz, et al.Pageof 12